Université de Lyon, CNRS, Université Claude Bernard Lyon 1, Institut des Sciences Analytiques, UMR 5280, 69100, Villeurbanne, France; Institut Lumière Matière, Université Claude Bernard Lyon 1, CNRS UMR 5306, 69622, Villeurbanne, France.
Institut Lumière Matière, Université Claude Bernard Lyon 1, CNRS UMR 5306, 69622, Villeurbanne, France; NH TherAguix S.A.S., 29 Chemin du Vieux Chêne, 38240, Meylan, France.
Anal Chim Acta. 2021 Nov 15;1185:339081. doi: 10.1016/j.aca.2021.339081. Epub 2021 Sep 18.
The knowledge of the fate of metal-containing nanoparticles in biological media in aqueous media is of utmost importance for the future use of these promising theranostic agents for clinical applications. A methodology based on the combination of TDA-ICP-MS and CE-ICP-MS was applied to study the degradation pathway of AGuIX, a phase 2 clinical ultrasmall gadolinium-containing nanoparticle. Nanoparticle size measurements and gadolinium speciation performed in different media (phosphate buffer, urine and serum) demonstrated an accelerated dissolution of AGuIX in serum, without any release of free gadolinium for each medium.
了解含金属纳米粒子在水相生物介质中的命运对于这些有前途的治疗诊断试剂未来在临床中的应用至关重要。本研究采用 TDA-ICP-MS 和 CE-ICP-MS 相结合的方法，研究了处于临床二期的超小顺磁钆纳米粒子 AGuIX 的降解途径。在不同介质（磷酸盐缓冲液、尿液和血清）中进行的纳米颗粒粒径测量和镓形态分析表明，AGuIX 在血清中溶解速度加快，而每种介质中均未检测到游离镓的释放。
